Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)
AuthorsJoffe, J. K.
Cafferty, F. H.
Rustin, G. J. S.
Sohaib, S. A.
Stenning, S. P.
Taylor, H. H.
Kaplan, R. S.
Huddart, R. A.
MetadataShow full item record
AbstractPURPOSE Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance is an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation is vital. The Trial of Imaging and Surveillance in Seminoma Testis (TRISST) assessed whether magnetic resonance images (MRIs) or a reduced scan schedule could be used without an unacceptable increase in advanced relapses. METHODS A phase III, noninferiority, factorial trial. Eligible participants had undergone orchiectomy for stage I seminoma with no adjuvant therapy planned. Random assignment was to seven CTs (6, 12, 18, 24, 36, 48, and 60 months); seven MRIs (same schedule); three CTs (6, 18, and 36 months); or three MRIs. The primary outcome was 6-year incidence of Royal Marsden Hospital stage ≥ IIC relapse (> 5 cm), aiming to exclude increases ≥ 5.7% (from 5.7% to 11.4%) with MRI (v CT) or three scans (v 7); target N = 660, all contributing to both comparisons. Secondary outcomes include relapse ≥ 3 cm, disease-free survival, and overall survival. Intention-to-treat and per-protocol analyses were performed. RESULTS Six hundred sixty-nine patients enrolled (35 UK centers, 2008-2014); mean tumor size was 2.9 cm, and 358 (54%) were low risk (< 4 cm, no rete testis invasion). With a median follow-up of 72 months, 82 (12%) relapsed. Stage ≥ IIC relapse was rare (10 events). Although statistically noninferior, more events occurred with three scans (nine, 2.8%) versus seven scans (one, 0.3%): 2.5% absolute increase, 90% CI (1.0 to 4.1). Only 4/9 could have potentially been detected earlier with seven scans. Noninferiority of MRI versus CT was also shown; fewer events occurred with MRI (two [0.6%] v eight [2.6%]), 1.9% decrease (–3.5 to –0.3). Per-protocol analyses confirmed noninferiority. Five-year survival was 99%, with no tumor-related deaths. CONCLUSION Surveillance is a safe management approach—advanced relapse is rare, salvage treatment successful, and outcomes excellent, regardless of imaging frequency or modality. MRI can be recommended to reduce irradiation; and no adverse impact on long-term outcomes was seen with a reduced schedule.
CitationJoffe JK, Cafferty FH, Murphy L, Rustin GJS, Sohaib SA, Gabe R, et al. Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022.
JournalJ Clin Oncol
- Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
- Authors: Porcaro AB, Antoniolli SZ, Maffei N, Beltrami P, Bassetto MA, Curti P
- Issue date: 2002 Jun
- Changing Practice Evaluation-Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols-Experience From a Supraregional Center.
- Authors: Tyrrell HEJ, Church DN, Joseph J, Traill ZC, Sullivan ME, Tuthill MH, Verrill CL, Pintus EP, Dallas NL, Rogers PB, Redgwell J, Protheroe AS
- Issue date: 2018 Jun
- Management of clinical stage I testicular pure seminoma. Report on 42 patients and review of the literature.
- Authors: Porcaro AB, Antoniolli SZ, Schiavone D, Maffei N, Bassetto MA, Curti P
- Issue date: 2002 Jun
- Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
- Authors: Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H
- Issue date: 2002 Nov 15
- Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).
- Authors: Aparicio J, Maroto P, García Del Muro X, Sánchez-Muñoz A, Gumà J, Margelí M, Sáenz A, Sagastibelza N, Castellano D, Arranz JA, Hervás D, Bastús R, Fernández-Aramburo A, Sastre J, Terrasa J, López-Brea M, Dorca J, Almenar D, Carles J, Hernández A, Germà JR
- Issue date: 2014 Nov